REGISTER
MedJ and Tonacea Announce Official Launch of the Huashan Awards for China Innovative Drugs

On December 12, Mr. Qirui Chen, founder of MedJ, and Dr. Zengjiang Cheng, founder of Tonacea (China Novel Drug R&D Community), jointly announced that the seven-member Management Committee and the 26-member Expert Review Committee for the Huashan Awards for China Innovative Drugs have been formed, officially kicking off the award’s launch and the selection process.

The Huashan Awards are jointly initiated by MedJ and Tonacea. Based on professional standards, international benchmarks, and public evaluation, the awards aim to identify value-based healthcare benchmarks and showcase “Chinese Exemplars” in China’s innovative drug sector.

How did the Huashan Awards originate?

At 10:00 a.m. on December 2, Mr. Qirui Chen, founder of MedJ, paid a courtesy visit to Dr. Yiman Zheng, Vice President of Medical Affairs at MSD China. On behalf of the Huashan Awards Management Committee, Chen presented Dr. Zheng with a formal letter of appointment as a review expert.

Dr. Yiman Zheng(Left)& Mr. Qirui Chen(Right)


Dr. Yiman Zheng holds a Ph.D. in Endocrinology from Shanghai Jiao Tong University School of Medicine (formerly Shanghai Second Medical University) and has more than 20 years of experience working in multinational medical device and pharmaceutical companies.

The idea for the Huashan Awards for innovative drugs in China originated from a conversation between Dr. Zheng and Mr. Qirui Chen half a year ago. During their discussion, both agreed that China’s innovative drug industry had reached a strategic inflection point: the sector was developing rapidly, its global influence was steadily expanding, and domestic market policies were trending more favorably. At this critical juncture, they began to reflect on what could be done to contribute to the industry.

Dr. Zheng proposed establishing a dedicated award for innovative drugs in China, citing the Prix Galien USA, a prestigious award in the biopharmaceutical field often referred to as the “Nobel Prize of Medicine,” as a model with significant global influence.

As a leading professional medical new media platform in China, MedJ already had successful experience in establishing the Taishan Awards. It was therefore entirely feasible to create a national award dedicated to China’s innovative drugs. Both parties agreed that identifying truly valuable innovative drugs based on sound principles, setting industry benchmarks, and documenting and supporting the development of China’s innovative drug sector would be of great significance.

One week later, Mr. Qirui Chen contacted his close friend of nearly 20 years, Dr. Zengjiang Cheng, founder of Tonacea, one of China’s most influential innovative drug R&D communities. Mr. Chen shared the concept of establishing the Huashan Awards for innovative drugs, and the two immediately found alignment, deciding to jointly initiate the China Innovative Drug Huashan Awards.

After half a year of deliberation, extensive communication with stakeholders, consultation, and detailed planning, the Huashan Awards for China Innovative Drugs have now officially commenced.

Mr. Qirui Chen(Left)& Dr. Zengjiang Chen


The Management Committee of the Huashan Awards is co-chaired by Mr. Qirui Chen, Honorary President of the China Pharmaceutical Innovation and Research Development Association, and Dr. Yaning Wang, a former FDA official. Mr. Qirui Chen, founder of MedJ, and Dr. Zengjiang Cheng, founder of Tonacea, serve as Co-Secretaries-General. Committee members include Dr. Chunlin Jin, Director of the Shanghai Health and Development Research Center; Dr. Yiman Zheng, Vice President of Medical Affairs at MSD China; and Rui Zhou, former pharmaceutical fund manager at Huitianfu Fund.

The expert review system comprises two panels: a Drug Product Review Committee with 15 experts and an Enterprise Review Committee with 11 experts. The panels include deans of pharmacy from four leading universities—Tsinghua University, Peking University, Shanghai Jiao Tong University, and Fudan University—as well as prominent innovative drug entrepreneurs, including the Chairman of Fosun Pharma, the CEO of Kelun-Biotech, the founder of Zejing Pharmaceuticals, and the founder of Duality Biologics. The committees also include professional healthcare investors from Sequoia Capital China, Legend Capital, Qiming Venture Partners, and SoftBank China Capital, along with former FDA officials, NIH clinical experts, and professionals from innovative drug media. Most reviewers possess strong international perspectives and professional backgrounds and are long-term participants and observers in the innovative drug industry.

Mr. Qirui Chen stated that as a medical new media platform, MedJ’s primary focus is on the clinical value of innovative drugs, alongside their level of innovation. With their international vision, professional expertise, and extensive experience, the panel of reviewers is expected to provide professional and reliable evaluation support for the Huashan Awards.

Dr. Zengjiang Cheng noted that Tonacea, as one of China’s most influential innovative drug R&D communities, has been deeply engaged in serving the innovative drug sector for nearly 20 years and has now entered a new era of robust growth. With support from all parties, he expressed confidence that MedJ and Tonacea will establish the Huashan Awards as the most credible award for innovative drugs in China.

0
0
Loading